Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) kicked off on Tuesday, down -9.71% from the previous trading day, before settling in for the closing price of $5.15. Over the past 52 weeks, AMLX has traded in a range of $1.58-$7.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1825.06%. While this was happening, its average annual earnings per share was recorded 57.97%. With a float of $66.62 million, this company’s outstanding shares have now reached $68.63 million.
Let’s determine the extent of company efficiency that accounts for 123 employees. In terms of profitability, gross margin is -43.43%, operating margin of -334.07%, and the pretax margin is -345.81%.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 25.22%, while institutional ownership is 56.35%. The most recent insider transaction that took place on Mar 31 ’25, was worth 37,806. In this transaction Chief Financial Officer of this company sold 10,896 shares at a rate of $3.47, taking the stock ownership to the 290,988 shares. Before that another transaction happened on Mar 31 ’25, when Company’s Chief Medical Officer sold 12,425 for $3.47, making the entire transaction worth $43,082. This insider now owns 194,375 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 57.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.51% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Take a look at Amylyx Pharmaceuticals Inc’s (AMLX) current performance indicators. Last quarter, stock had a quick ratio of 6.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.43, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.54 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Looking closely at Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), its last 5-days average volume was 1.03 million, which is a jump from its year-to-date volume of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 68.16%. Additionally, its Average True Range was 0.36.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 69.49%, which indicates a significant increase from 48.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.75% in the past 14 days, which was higher than the 78.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.92, while its 200-day Moving Average is $3.70. However, in the short run, Amylyx Pharmaceuticals Inc’s stock first resistance to watch stands at $5.04. Second resistance stands at $5.44. The third major resistance level sits at $5.63. If the price goes on to break the first support level at $4.45, it is likely to go to the next support level at $4.26. Should the price break the second support level, the third support level stands at $3.86.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
The company with the Market Capitalisation of 414.24 million has total of 89,084K Shares Outstanding. Its annual sales at the moment are 87,370 K in contrast with the sum of -301,740 K annual income. Company’s last quarter sales were recorded 420 K and last quarter income was -72,700 K.
